{
    "clinical_study": {
        "@rank": "163196", 
        "acronym": "SCARIS", 
        "arm_group": [
            {
                "arm_group_label": "Ecig 24 mg nicotine", 
                "arm_group_type": "Experimental", 
                "description": "Ecig 24 mg nicotine"
            }, 
            {
                "arm_group_label": "Ecig 0 mg nicotine", 
                "arm_group_type": "Sham Comparator", 
                "description": "Ecig 0 mg nicotine"
            }, 
            {
                "arm_group_label": "Nicotine free inhalator", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Nicotine free inhalator"
            }
        ], 
        "brief_summary": {
            "textblock": "It is well established in studies across several countries that tobacco smoking is more\n      prevalent among schizophrenic patients than the general population. Electronic cigarettes\n      (e-cigarettes) are becoming increasingly popular with smokers worldwide. To date there are\n      no large randomised trials of e-cigarettes in schizophrenic smokers. A well-designed trial\n      is needed to compare efficacy and safety of these products in this special population."
        }, 
        "brief_title": "Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.", 
        "condition": "Tobacco Smoking in Schizophrenic Patients", 
        "condition_browse": {
            "mesh_term": [
                "Schizophrenia", 
                "Smoking"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators have designed a randomized controlled trial investigating the efficacy and\n      safety of electronic cigarette. The trial will take the form of a prospective 12-month\n      randomized clinical study to evaluate smoking reduction, smoking abstinence and adverse\n      events in schizophrenic smokers not intending to quit. The investigators will also monitor\n      quality of life, neurocognitive functioning and measure participants' perception and\n      satisfaction of the product.\n\n      The main strengths of the SCARIS study are the following: it's the first large RCT on\n      schizophrenic patient, involving in and outpatient, evaluating the effect  of a three-arm\n      study design, and a long term of follow-up (52-weeks)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Schizophrenic subjects (according to DSM-IV-TR criteria) from throughout Sicily,\n             (Italy), who smoke tobacco cigarettes, in stable phase of illness.\n\n          -  smoke \u226510 factory made cig/day, for at least the past five years\n\n          -  age 18-65 years\n\n          -  in good general health\n\n          -  not currently attempting to quit smoking or wishing to do so in the next 30 days (a\n             specific test will be included to check their unwillingness to quit) 6 months\n\n          -  committed to follow the trial procedures.\n\n        Exclusion Criteria:\n\n          -  use of smokeless tobacco or nicotine replacement therapy\n\n          -  pregnancy or breastfeeding.\n\n          -  current or recent (less than 1 yr) past history of alcohol and/or drug abuse\n\n          -  other significant co-morbidities according to the Investigator's clinical assessment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "153", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979796", 
            "org_study_id": "SCARIS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ecig 24 mg nicotine", 
                "intervention_name": "Ecig 24 mg nicotine", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Ecig 0 mg nicotine", 
                "intervention_name": "Ecig 0 mg nicotine", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Nicotine free inhalator", 
                "intervention_name": "Nicotine free inhalator", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Addiction, Schizophrenia, Electronic cigarettes", 
        "lastchanged_date": "November 2, 2013", 
        "number_of_arms": "3", 
        "official_title": "Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning: Design of a Randomized Trial. Smoking Cessation And Reduction In Schizophrenia (The SCARIS Study)", 
        "other_outcome": {
            "description": "Quality of life, Neurocognitive Functioning and Psychopathological status will be assessed at each study visit by Quality of Life Scale (QLS),  Brief Assessment of Cognition in Schizophrenia (BACS) and Positive and Negative Symptoms Scale(PANSS), respectively\nParticipants' perception and liking of the product will be assessed by asking to rate their level of satisfaction with the products compared to their own cigarettes using a visual analogue scale (VAS) from 0 to 10 points (0 = being 'completely unsatisfied', 10 being = 'fully satisfied'); using the same scale, they will also rate how much they miss their own brand (0 = being 'did not miss it at all', 10 being = 'missed too much') and whether they would recommend it to a friend/relative (0 = being 'not recommended at all', 10 being = 'absolutely recommended').", 
            "measure": "Evaluation of neurocognitive functioning", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Catania", 
                "last_name": "Pasquale Caponnetto, Assis Prof", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Catania", 
                "last_name": "Eugenio Aguglia, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Catania", 
                "last_name": "Giuseppe Minutolo, Assis prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Abstinence from smoking, defined as complete self-reported abstinence from tobacco smoking - not even a puff (together with an eCO concentration of \u22647 ppm), will be calculated at each study visit (\"quitters\").", 
            "measure": "smoking cessation", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979796"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universita degli Studi di Catania", 
            "investigator_full_name": "Riccardo Polosa", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "A \u226550% reduction in the number of cig/day from baseline, defined as self-reported reduction in the number of cig/day (\u226550%) compared to baseline (together with an eCO levels reduction, to objectively document a reduction from baseline), will be calculated at each study visit (\"reducers\").\nSmokers who will not satisfy the criteria of \"reducers\" and \"quitters\" will be defined \"non responders\".", 
            "measure": "Smoking reduction", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "source": "Universita degli Studi di Catania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universita degli Studi di Catania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}